About Mitochondrial inner membrane protein OXA1L
Mitochondrial inner membrane protein OXA1L (OXA1L) is a protein
from Homo sapiens identified by UniProt accession
Q15070, 435 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Mitochondrial inner membrane protein OXA1L |
| UniProt accession | Q15070 |
| Gene | OXA1L |
| Organism | Homo sapiens |
| Length | 435 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (36)
Diseases linked to this target (Open Targets).
- mitochondrial disease · score 0.42
- lysinuric protein intolerance · score 0.33
- Familial prostate cancer · score 0.11
- prostate cancer · score 0.11
- myoepithelial tumor · score 0.11
- prostate carcinoma · score 0.11
- intraocular pressure measurement · score 0.10
- heart failure · score 0.05
- Duane retraction syndrome · score 0.04
- overweight body mass index status · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15070-F1 | alphafold | PREDICTED | 73.75 | — |
Amino-acid sequence (435 residues)
MAMGLMCGRR ELLRLLQSGR RVHSVAGPSQ WLGKPLTTRL LFPAAPCCCR PHYLFLAASG PRSLSTSAIS FAEVQVQAPP VVAATPSPTA VPEVASGETA DVVQTAAEQS FAELGLGSYT PVGLIQNLLE FMHVDLGLPW WGAIAACTVF ARCLIFPLIV TGQREAARIH NHLPEIQKFS SRIREAKLAG DHIEYYKASS EMALYQKKHG IKLYKPLILP VTQAPIFISF FIALREMANL PVPSLQTGGL WWFQDLTVSD PIYILPLAVT ATMWAVLELG AETGVQSSDL QWMRNVIRMM PLITLPITMH FPTAVFMYWL SSNLFSLVQV SCLRIPAVRT VLKIPQRVVH DLDKLPPREG FLESFKKGWK NAEMTRQLRE REQRMRNQLE LAARGPLRQT FTHNPLLQPG KDNPPNIPSS SSKPKSKYPW HDTLG
Explore Mitochondrial inner membrane protein OXA1L with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets